Caring Brands, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Caring Brands, Inc. performed this year. My goal is to cut through the corporate jargon and focus on what matters for your investment.

1. What does this company do?

Caring Brands is a wellness company focused on skin and hair care. They buy products backed by science and bring them to market. Their lineup includes Photocil (for vitiligo and psoriasis), Hair Enzyme Booster (JW-700) (which helps minoxidil work better), and a pipeline of eczema and sun protection products. They operate as a lean business, outsourcing manufacturing and distribution to keep costs low.

2. Financial performance: The "Big Picture"

To be blunt, the company is losing money while trying to grow.

• The Losses: They reported a $6.28 million loss for 2025, up from a $1.52 million loss in 2024. This jump happened because they spent 215% more on research and 180% more on administrative costs during a leadership change.
• Revenue: They brought in $412,000 in 2025, barely more than the $385,000 from 2024. They are currently in a "burn phase," where they spend about $15 for every $1 they earn.

3. Major wins and challenges

• Product Launches: They launched the Hair Enzyme Booster in late 2024. While Photocil sells steadily in India, its previous U.S. launch struggled with marketing. They have set aside $1.2 million to try again in 2026, pending final FDA approval.
• Global Ambitions: They are licensing products to partners in India and targeting over 30 countries across Africa, the Middle East, and Asia. A deal with Taisho Pharmaceutical—a $4 billion company—includes an upfront payment of $250,000 and up to $1.5 million in future bonuses if they hit certain goals.
• Leadership: A new CEO and Chairman joined in July 2025. They are currently focused on cutting non-essential administrative costs by 15% over the next year.

4. Financial health

This is the most important section. The company relies on loans and selling stock to fund operations. As of June 30, 2025, they had $850,000 in cash but $4.2 million in debt due soon. With 13.3 million shares outstanding, the company is valued at about $18.6 million, though this price fluctuates.

5. Key risks for investors

• Dilution: To cover their $6.28 million loss, the company issued 2.1 million new shares this year. Future share sales are likely, which would reduce your ownership percentage.
• "Going Concern" Risk: Auditors have warned that the company may need to raise another $3 million to $5 million to survive the next 12 months.
• Execution Risk: The company must prove it can successfully sell products directly to U.S. customers.
• Regulatory Hurdles: Turning products into FDA-approved drugs is expensive and time-consuming. If the FDA rejects their applications, their U.S. revenue plans could be significantly impacted.

Final Thought for Investors: Caring Brands is currently a high-risk, speculative play. Because they are burning cash faster than they are generating revenue, their survival depends entirely on their ability to raise more capital and successfully execute their U.S. product relaunch. Before investing, consider whether you are comfortable with the high probability of further share dilution and the company's urgent need for new funding.